• No sign of paclitaxel-related mortality risk in VOYAGER PAD cohort

    5 days ago - By Healio

    At 3.5 years after lower-extremity revascularization, there was no difference in mortality in the VOYAGER PAD cohort between patients with peripheral artery disease treated with paclitaxel-coated devices and those not treated with them.
    In addition, the beneficial treatment effect of rivaroxaban was consistent regardless of whether patients underwent an endovascular procedure with paclitaxel-coated devices, researchers reported at TCT Connect.
    “The objectives of the current analysis were in patients enrolled in VOYAGER who underwent endovascular lower-extremity
    Read more ...